Key result
Transcatheter closure treats 85-90% of secundum atrial septal defects, but its success is constrained by anatomical, device-related, physiological, and complication-related limitations.
While transcatheter closure is feasible for the vast majority of secundum ASDs, physicians must carefully evaluate anatomical, device-related, and physiological limitations to ensure procedural success.
Answers are grounded in this paper and cite their sources.
Clinicians must evaluate anatomical and device constraints before transcatheter ASD closure; leaves open device innovation for ineligible anatomies.
Transcatheter closure is a widespread technique used to treat secundum atrial septal defects (ASDs). When compared to surgery, it provides a less invasive approach with quicker recovery and reduced physical and psychological impact. Nowadays, almost 85-90% of all secundum ASD can be closed by using a transcatheter approach. However, several limitations may have a significant impact on the feasibility and success of percutaneous ASD closure. Limitations can be grouped as: (I) anatomical; (II) device-related; (III) associated defects and natural history associated issues; (IV) physiological; (V) complications. Physician should be aware of potential limits of percutaneous ASD closure.
No takes yet. Share an insight, caveat, or question.
Faccini et al. (2018) conducted a review in Secundum atrial septal defects (ASDs). Transcatheter closure vs. Surgery was evaluated. Transcatheter closure treats 85-90% of secundum atrial septal defects, but its success is constrained by anatomical, device-related, physiological, and complication-related limitations.
Synapse has enriched 10 related papers. Consider them for comparative context: